At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 446 enrolled
Drug / intervention
onabotulinumtoxinA +1 morebiological
Likely dose
onabotulinumtoxinA 24 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines
In Brief
A Phase 3 clinical trial evaluating onabotulinumtoxinA and normal saline for Lateral Canthus Rhytides and Crow's Feet Lines. Completed, enrolled 446 participants across 4 sites in 4 countries.
Detailed Summary
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthus Rhytides, Crow's Feet Lines
CountriesBelgium, Canada, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartOct 2010
Primary CompletionApr 2011
Study CompletionJul 2011
TodayJul 2026
First PostedAug 27, 2010
Enrollment StartOct 1, 2010
Primary CompletionApr 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.8 years ago
Interventions
onabotulinumtoxinAbiological
24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
normal salinedrug
Injected into bilateral Crow's Feet Line areas on Day 1